Question:medium
Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?
Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?
Show Hint
Recombinant IL-11 that boosts megakaryocyte progenitors and platelet output.
Updated On: Jun 24, 2026
- Filgrastim
- Oprelvekin
- Erythropoietin
- Anagrelide
Show Solution
The Correct Option is B
Solution and Explanation
Step 1: We need a growth factor that drives the megakaryocyte line to lift platelets after cancer chemotherapy.
Step 2: That role belongs to oprelvekin, which is interleukin-11 made by recombinant technology. It expands megakaryocyte progenitors and pushes their maturation, so the marrow churns out more platelets. Its licensed indication is chemotherapy-associated thrombocytopenia.
Step 3: The distractors each act on a different lineage or in the wrong direction. Filgrastim (G-CSF) targets neutrophils, erythropoietin targets red cells, and anagrelide is given to bring a high platelet count down in thrombocythemia. None of them raises platelets via megakaryocyte progenitor stimulation.
Step 4: The answer is therefore oprelvekin.
\[\boxed{\text{Oprelvekin}}\]
Step 2: That role belongs to oprelvekin, which is interleukin-11 made by recombinant technology. It expands megakaryocyte progenitors and pushes their maturation, so the marrow churns out more platelets. Its licensed indication is chemotherapy-associated thrombocytopenia.
Step 3: The distractors each act on a different lineage or in the wrong direction. Filgrastim (G-CSF) targets neutrophils, erythropoietin targets red cells, and anagrelide is given to bring a high platelet count down in thrombocythemia. None of them raises platelets via megakaryocyte progenitor stimulation.
Step 4: The answer is therefore oprelvekin.
\[\boxed{\text{Oprelvekin}}\]
Was this answer helpful?
0
